drugset
drugset / Trial / NCT05255822

INNA-051 Influenza Challenge Study

NCT05255822 ↗

Phase 2 Completed 123 enrolled ENA Respiratory Pty Ltd
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a Phase 2, randomized, double-blind, placebo-controlled study of INNA-051 in healthy adults, administered prior to administration of an influenza challenge virus. This study will evaluate 2 active dose levels of INNA-051 and placebo.

Timeline

Start
2022-02-28
Primary completion
2022-08-23
Completion
2022-08-23

Drugs

EvaluationDrugModalityDoseRoute
Subject INNA-051 Unknown — Intranasal

Indications

No indication recorded.